Tony Lahoutte

Prof Dr Tony Lahoutte is head of the department of nuclear medicine at UZ Brussel and head of the molecular imaging research unit at the Vrije Universiteit Brussel (VUB) in Belgium. In 2014 he co-founded the company Camel-IDS NV that is developing a pipeline of radio-immuno therapeutics where he is CSO. He obtained his medical degree in 1998 and started his research activities in combination with a residency program in nuclear medicine. His current research is focused on the development and clinical translation of molecular imaging probes and targeted radionuclide therapies for the detection and treatment of cancer.

Prof Dr Tony Lahoutte is head of the department of nuclear medicine at UZ Brussel and head of the molecular imaging research unit at the Vrije Universiteit Brussel (VUB) in Belgium. In 2014 he co-founded the company Camel-IDS NV that is developing a pipeline of radio-immuno therapeutics where he is CSO. He obtained his medical degree in 1998 and started his research activities in combination with a residency program in nuclear medicine. His current research is focused on the development and clinical translation of molecular imaging probes and targeted radionuclide therapies for the detection and treatment of cancer.